Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients
Objective: The potential contribution of asymmetric dimethylarginine (ADMA) and high-sensitivity C reactive protein (hsCRP) to endothelial dysfunction in APS patients has not been studied in detail, until now. The study involved 105 APS patients (59 diagnosed with primary APS (PAPS) and 46 APS assoc...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/20/12309 |
| _version_ | 1797472767295094784 |
|---|---|
| author | Natasa Stanisavljevic Ljudmila Stojanovich Aleksandra Djokovic Brankica Todic Violeta Dopsaj Jovica Saponjski Dusan Saponjski Olivera Markovic Cristina Belizna Marija Zdravkovic Dragomir Marisavljevic |
| author_facet | Natasa Stanisavljevic Ljudmila Stojanovich Aleksandra Djokovic Brankica Todic Violeta Dopsaj Jovica Saponjski Dusan Saponjski Olivera Markovic Cristina Belizna Marija Zdravkovic Dragomir Marisavljevic |
| author_sort | Natasa Stanisavljevic |
| collection | DOAJ |
| description | Objective: The potential contribution of asymmetric dimethylarginine (ADMA) and high-sensitivity C reactive protein (hsCRP) to endothelial dysfunction in APS patients has not been studied in detail, until now. The study involved 105 APS patients (59 diagnosed with primary APS (PAPS) and 46 APS associated with systemic lupus erythematosus (SAPS)) who were compared to 40 controls. Endothelial dysfunction was assessed by measurement of flow-mediated dilatation (FMD) and glyceryl trinitrate dilatation (NMD) of the brachial artery. ADMA (micromol/L) was analyzed by ELISA. Results: FMD in patients with APS was significantly lower than that of the controls (<i>p</i> < 0.001), with no difference between the PAPS and the SAPS groups. ADMA and hsCRP concentrations were significantly higher in the patient cohort than in the control group (<i>p</i> < 0.001, <i>p</i> = 0.006, respectively), as was the case with the SAPS group as compared to the PAPS group (<i>p</i> < 0.001, <i>p</i> = 0.022, respectively). FMD impairment correlated to ADMA (ρ 0.472, <i>p</i> < 0.001) and to hsCRP (ρ 0.181, <i>p</i> = 0.033). In the regression model, the ADMA concentration confirmed the strength of its association (B 0.518, SE 0.183, Wald 8.041, <i>p</i> = 0.005, Exp(B) 1.679, 95% CI 1.174–2.402) to FMD impairment. The synergistic probability model of ADMA and hsCRP caused FMD impairment when the positivity of β2GPIIgG was added. ADMA may be used as a simple and low-cost tool for verifying the presence of endothelial dysfunction in APS patients. According to the results of the study, we could presume that hsCRP, together with aPL, has a preparatory effect on the endothelium in causing endothelial dysfunction. |
| first_indexed | 2024-03-09T20:06:50Z |
| format | Article |
| id | doaj.art-835fa87d1c94438d9cb9d21e90b67e5b |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T20:06:50Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-835fa87d1c94438d9cb9d21e90b67e5b2023-11-24T00:30:39ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-10-0123201230910.3390/ijms232012309Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome PatientsNatasa Stanisavljevic0Ljudmila Stojanovich1Aleksandra Djokovic2Brankica Todic3Violeta Dopsaj4Jovica Saponjski5Dusan Saponjski6Olivera Markovic7Cristina Belizna8Marija Zdravkovic9Dragomir Marisavljevic10University Clinical Center “Bezanijska kosa”, Bezanijska kosa bb, 11080 Belgrade, SerbiaMedical Faculty, University of Belgrade, 11000 Belgrade, SerbiaUniversity Clinical Center “Bezanijska kosa”, Bezanijska kosa bb, 11080 Belgrade, SerbiaUniversity Clinical Center “Bezanijska kosa”, Bezanijska kosa bb, 11080 Belgrade, SerbiaFaculty of Pharmacy, University of Belgrade, 11000 Belgrade, SerbiaMedical Faculty, University of Belgrade, 11000 Belgrade, SerbiaMedical Faculty, University of Belgrade, 11000 Belgrade, SerbiaUniversity Clinical Center “Bezanijska kosa”, Bezanijska kosa bb, 11080 Belgrade, SerbiaInternal Medicine Department Clinique de l’Anjou, Angers, Vascular and Coagulation Department, University Hospital Angers, 49100 Angers, FranceUniversity Clinical Center “Bezanijska kosa”, Bezanijska kosa bb, 11080 Belgrade, SerbiaFaculty of Pharmacy, University of Belgrade, 11000 Belgrade, SerbiaObjective: The potential contribution of asymmetric dimethylarginine (ADMA) and high-sensitivity C reactive protein (hsCRP) to endothelial dysfunction in APS patients has not been studied in detail, until now. The study involved 105 APS patients (59 diagnosed with primary APS (PAPS) and 46 APS associated with systemic lupus erythematosus (SAPS)) who were compared to 40 controls. Endothelial dysfunction was assessed by measurement of flow-mediated dilatation (FMD) and glyceryl trinitrate dilatation (NMD) of the brachial artery. ADMA (micromol/L) was analyzed by ELISA. Results: FMD in patients with APS was significantly lower than that of the controls (<i>p</i> < 0.001), with no difference between the PAPS and the SAPS groups. ADMA and hsCRP concentrations were significantly higher in the patient cohort than in the control group (<i>p</i> < 0.001, <i>p</i> = 0.006, respectively), as was the case with the SAPS group as compared to the PAPS group (<i>p</i> < 0.001, <i>p</i> = 0.022, respectively). FMD impairment correlated to ADMA (ρ 0.472, <i>p</i> < 0.001) and to hsCRP (ρ 0.181, <i>p</i> = 0.033). In the regression model, the ADMA concentration confirmed the strength of its association (B 0.518, SE 0.183, Wald 8.041, <i>p</i> = 0.005, Exp(B) 1.679, 95% CI 1.174–2.402) to FMD impairment. The synergistic probability model of ADMA and hsCRP caused FMD impairment when the positivity of β2GPIIgG was added. ADMA may be used as a simple and low-cost tool for verifying the presence of endothelial dysfunction in APS patients. According to the results of the study, we could presume that hsCRP, together with aPL, has a preparatory effect on the endothelium in causing endothelial dysfunction.https://www.mdpi.com/1422-0067/23/20/12309antiphospholipid syndromelupus erythematosussystemicinflammation |
| spellingShingle | Natasa Stanisavljevic Ljudmila Stojanovich Aleksandra Djokovic Brankica Todic Violeta Dopsaj Jovica Saponjski Dusan Saponjski Olivera Markovic Cristina Belizna Marija Zdravkovic Dragomir Marisavljevic Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients International Journal of Molecular Sciences antiphospholipid syndrome lupus erythematosus systemic inflammation |
| title | Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients |
| title_full | Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients |
| title_fullStr | Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients |
| title_full_unstemmed | Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients |
| title_short | Asymmetric Dimethylarginine Is a Marker of Endothelial Dysfunction in Thrombotic Antiphospholipid Syndrome Patients |
| title_sort | asymmetric dimethylarginine is a marker of endothelial dysfunction in thrombotic antiphospholipid syndrome patients |
| topic | antiphospholipid syndrome lupus erythematosus systemic inflammation |
| url | https://www.mdpi.com/1422-0067/23/20/12309 |
| work_keys_str_mv | AT natasastanisavljevic asymmetricdimethylarginineisamarkerofendothelialdysfunctioninthromboticantiphospholipidsyndromepatients AT ljudmilastojanovich asymmetricdimethylarginineisamarkerofendothelialdysfunctioninthromboticantiphospholipidsyndromepatients AT aleksandradjokovic asymmetricdimethylarginineisamarkerofendothelialdysfunctioninthromboticantiphospholipidsyndromepatients AT brankicatodic asymmetricdimethylarginineisamarkerofendothelialdysfunctioninthromboticantiphospholipidsyndromepatients AT violetadopsaj asymmetricdimethylarginineisamarkerofendothelialdysfunctioninthromboticantiphospholipidsyndromepatients AT jovicasaponjski asymmetricdimethylarginineisamarkerofendothelialdysfunctioninthromboticantiphospholipidsyndromepatients AT dusansaponjski asymmetricdimethylarginineisamarkerofendothelialdysfunctioninthromboticantiphospholipidsyndromepatients AT oliveramarkovic asymmetricdimethylarginineisamarkerofendothelialdysfunctioninthromboticantiphospholipidsyndromepatients AT cristinabelizna asymmetricdimethylarginineisamarkerofendothelialdysfunctioninthromboticantiphospholipidsyndromepatients AT marijazdravkovic asymmetricdimethylarginineisamarkerofendothelialdysfunctioninthromboticantiphospholipidsyndromepatients AT dragomirmarisavljevic asymmetricdimethylarginineisamarkerofendothelialdysfunctioninthromboticantiphospholipidsyndromepatients |